Pharm-Olam Continues Global Expansion; Adds Full-Service Coverage in Asia-Pacific Region
Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce its expansion of Phase I-IV clinical trial services into the Asia-Pacific region.
This expansion includes the opening of legal entities in Vietnam, Philippines, South Korea, Malaysia, Thailand and Taiwan.
“In response to requests coming in from our clients, we have begun expanding our services into the Asia-Pacific region,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). He continued, “We anticipate significant study growth in the region over the next few years, and we are now poised to guide our clients in the development process in these promising yet often overlooked markets.”
Suri added, “The successes we’ve shared have been a result of offering our clients solutions for their unique needs. Our Asia-Pacific expansion efforts will allow us to offer comprehensive and flexible solutions in a timely and efficient manner. We look forward to continuing to support our clients globally.”
For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact email@example.com .
About Pharm-Olam International Group
Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com .
Mark Eberhardt, +1-713-599-7350
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
BOEHRINGER-INGELHEIM11.12.2017 14:02 | pressemeddelelse
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
NY-VALENCE-GROUP11.12.2017 13:49 | pressemeddelelse
Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses
SMITH-&-NEPHEW11.12.2017 11:20 | pressemeddelelse
Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care
UAE-FNC11.12.2017 10:43 | pressemeddelelse
Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament
GA-CELLTRION-HEALTHCARE11.12.2017 09:02 | pressemeddelelse
Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma
DIMOCO-EUROPE11.12.2017 09:02 | pressemeddelelse
Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum